Date: 2013-10-08
Type of information: R&D agreement
Compound:
Company: Horizon Discovery (UK) Blueprint Medicines (UK)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
collaboration
Action mechanism:
Disease:
Details: * On October 8, 2013, Horizon Discovery, a provider of research tools to support the development of personalized medicines, has announced it has signed a research service agreement with Blueprint Medicines, a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Under the terms of the deal Horizon will support Blueprint’s “New Targets” discovery platform by deploying its X-MAN™ isogenic cell lines. Horizon will use its proprietary platform and expertise to screen a selection of Blueprint’s unique and highly selective kinase inhibitor tool compounds on a panel of 26 X-MAN isogenic cell lines. Performing screens on X-MAN cell lines will provide valuable insights into elucidating synthetic lethal interactions with approximately 100 kinase targets in various cancer subtypes.
Horizon provides definitive and controlled preclinical model systems through the use of isogenic cell lines, where the genetic modification of interest can be directly compared to its matched normal cell. These cell lines have been generated through the GENESIS™ genome editing platform, which now includes ZFN and CRISPR, as well as the company’s proprietary rAAV technology. The use of panels of these isogenic cell lines allows molecularly-defined cellular models to be systematically profiled, thereby providing a powerful tool for the investigation of sensitivity and resistance to cancer therapeutics. Horizon has recently launched this as a service broadly available to academic and commercial customers.
Financial terms: Financial terms were not disclosed.
Latest news:
